MedTrace Logo

Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis

NCT02473601 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-08-21

No results posted yet for this study

Summary

Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon

Conditions

  • Liver Dysfunction

Interventions

DRUG

Mivacurium Chloride

Anesthesia induction: Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes. Anesthesia maintenance: Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane.

Sponsors & Collaborators

  • Jiangsu Nhwa Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • zhao xiaoyong, master · Shanxi Province, Xi'an city Baqiao District Temple Road, No. 1 Tangdu Hospital

  • sun meiyan, master · Shanxi Province, Xi'an city Baqiao District Temple Road, No. 1 Tangdu Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473601 on ClinicalTrials.gov